Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 5
2012 3
2013 2
2014 2
2015 3
2016 3
2017 6
2018 1
2019 9
2020 7
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

39 results
Results by year
Filters applied: . Clear all
Page 1
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.
Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E. Garcia-Manero G, et al. Blood Adv. 2019 Feb 26;3(4):508-518. doi: 10.1182/bloodadvances.2018027409. Blood Adv. 2019. PMID: 30760466 Free PMC article. Clinical Trial.
Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined with azacitidine. ...Patients received pracinostat 60 mg/d, 3 d/wk, for 3 consecuti
Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has s
Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P, Vachhani P, Cortes JE. Bose P, et al. Curr Treat Options Oncol. 2017 Mar;18(3):17. doi: 10.1007/s11864-017-0456-2. Curr Treat Options Oncol. 2017. PMID: 28286924 Review.
Although no new drug has been approved for AML in over four decades, with the exception of gemtuzumab ozogamycin, which was subsequently withdrawn, there is progress on the horizon with the possible regulatory approval soon of agents such as CPX-351 and midostaurin, the Food and …
Although no new drug has been approved for AML in over four decades, with the exception of gemtuzumab ozogamycin, which was subsequently wit …
Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J, Li N, Liu B, Ling J, Yang W, Pang X, Li T. Chen J, et al. Life Sci. 2020 May 1;248:117469. doi: 10.1016/j.lfs.2020.117469. Epub 2020 Feb 25. Life Sci. 2020. PMID: 32109485
KEY FINDINGS: Our results demonstrated that SB939 at 0.5-1 mumol/L markedly impaired the chemotactic motility of breast cancer cells. ...SIGNIFICANCE: Our findings indicate that SB939 may be an effective therapeutic option for treating advanced breast cancer....
KEY FINDINGS: Our results demonstrated that SB939 at 0.5-1 mumol/L markedly impaired the chemotactic motility of breast cancer cells. …
A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.
Bose P, Swaminathan M, Pemmaraju N, Ferrajoli A, Jabbour EJ, Daver NG, DiNardo CD, Alvarado Y, Yilmaz M, Huynh-Lu J, Qiao W, Wang X, Matamoros A, Zhou L, Pierce S, Schroeder KD, Kantarjian HM, Verstovsek S. Bose P, et al. Leuk Lymphoma. 2019 Jul;60(7):1767-1774. doi: 10.1080/10428194.2018.1543876. Epub 2019 Jan 11. Leuk Lymphoma. 2019. PMID: 30632841 Free PMC article. Clinical Trial.
All patients discontinued pracinostat and are currently off-study. Pracinostat interruptions and dose reductions were frequent, often due to worsening anemia. These findings do not support continued development of pracinostat in myelofibrosis....
All patients discontinued pracinostat and are currently off-study. Pracinostat interruptions and dose reductions were frequent …
Minor structural modifications to Pracinostat produce big changes in its biological responses.
Jia R, Sun P, Zhang Y, Ge Y, Yu N. Jia R, et al. Chem Biol Drug Des. 2019 Aug;94(2):1488-1493. doi: 10.1111/cbdd.13527. Epub 2019 Apr 29. Chem Biol Drug Des. 2019. PMID: 30932330
A series of compounds similar to Pracinostat that contained benzimidazole ring and N-hydroxyacrylamide attached at 5- or 6-position were designed, synthesized, and evaluated as HDAC inhibitors. ...
A series of compounds similar to Pracinostat that contained benzimidazole ring and N-hydroxyacrylamide attached at 5- or 6-position w …
Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.
Ganai SA. Ganai SA. Pharm Biol. 2016 Sep;54(9):1926-35. doi: 10.3109/13880209.2015.1135966. Epub 2016 Feb 5. Pharm Biol. 2016. PMID: 26853619 Review.
Hydroxamate HDACi, including vorinostat, have shown encouraging results in haematological malignancies, but the poor pharmacokinetic of these inhibitors leads to insufficient tumour concentration limiting their application against solid malignancies. Objective This article deals …
Hydroxamate HDACi, including vorinostat, have shown encouraging results in haematological malignancies, but the poor pharmacokinetic of thes …
HDAC Inhibitors in Acute Myeloid Leukemia.
San José-Enériz E, Gimenez-Camino N, Agirre X, Prosper F. San José-Enériz E, et al. Cancers (Basel). 2019 Nov 14;11(11):1794. doi: 10.3390/cancers11111794. Cancers (Basel). 2019. PMID: 31739588 Free PMC article. Review.
Although so far the results with HDACi in clinical trials in AML have been modest, there are some encouraging data from treatment with the HDACi Pracinostat in combination with DNA demethylating agents....
Although so far the results with HDACi in clinical trials in AML have been modest, there are some encouraging data from treatment with the H …
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.
Yalniz FF, Berdeja JG, Maris MB, Lyons RM, Reeves JA Jr, Essell JH, Patel P, Sekeres M, Hughes A, Mappa S, Garcia-Manero G. Yalniz FF, et al. Br J Haematol. 2020 Feb;188(3):404-412. doi: 10.1111/bjh.16173. Epub 2019 Aug 29. Br J Haematol. 2020. PMID: 31468521 Clinical Trial.
This phase II study explored the benefit of adding pracinostat to HMAs in MDS patients who did not respond to single-agent HMA treatment. ...Frequent dose modifications/early discontinuation resulted in suboptimal drug exposure. A reduced pracinostat dose may improv …
This phase II study explored the benefit of adding pracinostat to HMAs in MDS patients who did not respond to single-agent HMA treatm …
Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics.
Gilani JA, Ashfaq MA, Mansoor AE, Abdul Jabbar A, Siddiqui T, Khan M. Gilani JA, et al. Asian Pac J Cancer Prev. 2019 Jun 1;20(6):1691-1699. doi: 10.31557/APJCP.2019.20.6.1691. Asian Pac J Cancer Prev. 2019. PMID: 31244289 Free PMC article. Review.
These include JAK inhibitors like ruxolitinib, heat shock protein-90 inhibitors like ganetespib, histone deacetylase inhibitors including panobinostat, pracinostat, vorinostat and givinostat, hypomethylating agents like decitabine, hedgehog inhibitors like glasdegib, PI3K, …
These include JAK inhibitors like ruxolitinib, heat shock protein-90 inhibitors like ganetespib, histone deacetylase inhibitors including pa …
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Abaza YM, Kadia TM, Jabbour EJ, Konopleva MY, Borthakur G, Ferrajoli A, Estrov Z, Wierda WG, Alfonso A, Chong TH, Chuah C, Koh LP, Goh BC, Chang JE, Durkes DE, Foudray MC, Kantarjian HM, Dong XQ, Garcia-Manero G. Abaza YM, et al. Cancer. 2017 Dec 15;123(24):4851-4859. doi: 10.1002/cncr.30949. Epub 2017 Aug 25. Cancer. 2017. PMID: 28841236 Free PMC article. Clinical Trial.
Pracinostat is reported to have modest clinical activity in patients with advanced solid tumors. ...METHODS: Pracinostat was administered orally 3 times a week for 3 weeks on a 28-day cycle. ...
Pracinostat is reported to have modest clinical activity in patients with advanced solid tumors. ...METHODS: Pracinostat was a
39 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page